Empagliflozin May Be Poised To Gain CV Indication

–FDA reviewers have raised no major questions ahead of Tuesday’s advisory panel meeting. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will likely lend its support to an important new expanded indication for empagliflozin (Jardiance, Boehringer Ingelheim). The new indication is to reduce the risk of all-cause mortality by reducing the incidence of cardiovascular death,...Click here to continue reading...

Source: CardioBrief - June 24, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events advisory panel CVOT empagliflozin FDA outcomes trials Source Type: blogs